Historical Valuation
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
CureVac NV (CVAC) has a current Price-to-Book (P/B) ratio of NaN. Compared to its 3-year average P/B ratio of 1.88 , the current P/B ratio is approximately NaN% higher. Relative to its 5-year average P/B ratio of 4.93, the current P/B ratio is about NaN% higher. CureVac NV (CVAC) has a Forward Free Cash Flow (FCF) yield of approximately NaN%. Compared to its 3-year average FCF yield of -25.30%, the current FCF yield is approximately NaN% lower. Relative to its 5-year average FCF yield of -21.62% , the current FCF yield is about NaN% lower.
P/B
Median3y
1.88
Median5y
4.93
FCF Yield
Median3y
-25.30
Median5y
-21.62
Competitors Valuation Multiple
AI Analysis for CVAC
The average P/S ratio for CVAC competitors is 11.57, providing a benchmark for relative valuation. CureVac NV Corp (CVAC.O) exhibits a P/S ratio of 10.97, which is -5.24% above the industry average. Given its robust revenue growth of -89.04%, this premium appears unsustainable.
Performance Decomposition
AI Analysis for CVAC
1Y
3Y
5Y
Market capitalization of CVAC increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of CVAC in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is CVAC currently overvalued or undervalued?
CureVac NV (CVAC) is now in the Fair zone, suggesting that its current forward PS ratio of NaN is considered Fairly compared with the five-year average of -10.61. The fair price of CureVac NV (CVAC) is between to according to relative valuation methord.
What is CureVac NV (CVAC) fair value?
CVAC's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of CureVac NV (CVAC) is between to according to relative valuation methord.
How does CVAC's valuation metrics compare to the industry average?
The average P/S ratio for CVAC's competitors is 11.57, providing a benchmark for relative valuation. CureVac NV Corp (CVAC) exhibits a P/S ratio of 10.97, which is -5.24% above the industry average. Given its robust revenue growth of -89.04%, this premium appears unsustainable.
What is the current P/B ratio for CureVac NV (CVAC) as of Jan 10 2026?
As of Jan 10 2026, CureVac NV (CVAC) has a P/B ratio of NaN. This indicates that the market values CVAC at NaN times its book value.
What is the current FCF Yield for CureVac NV (CVAC) as of Jan 10 2026?
As of Jan 10 2026, CureVac NV (CVAC) has a FCF Yield of NaN%. This means that for every dollar of CureVac NV’s market capitalization, the company generates NaN cents in free cash flow.
What is the current Forward P/E ratio for CureVac NV (CVAC) as of Jan 10 2026?
As of Jan 10 2026, CureVac NV (CVAC) has a Forward P/E ratio of NaN. This means the market is willing to pay $NaN for every dollar of CureVac NV’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for CureVac NV (CVAC) as of Jan 10 2026?
As of Jan 10 2026, CureVac NV (CVAC) has a Forward P/S ratio of NaN. This means the market is valuing CVAC at $NaN for every dollar of expected revenue over the next 12 months.